Related Experiment Videos
First versus second eye intravitreal ranibizumab therapy for wet AMD
Mohamed A Eldaly1, Caroline Styles
1Ophthalmology Department, Cairo University, Giza, Egypt. mohamedahmedeldaly@yahoo.com
Retina (Philadelphia, Pa.)
|March 17, 2009
Summary
Intravitreal ranibizumab improves vision in both first and second eyes for wet age-related macular degeneration. While second eyes start with better vision, both groups achieve significant visual gains.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacological Treatments
Background:
- Wet age-related macular degeneration (AMD) is a leading cause of vision loss.
- Intravitreal ranibizumab is a common treatment for wet AMD.
- Treatment outcomes can differ based on the eye's initial visual status.
Purpose of the Study:
- To compare short-term visual outcomes of intravitreal ranibizumab in first eyes versus second eyes with wet AMD.
- To assess visual acuity and contrast sensitivity changes after treatment.
Main Methods:
- Seventy-five patients receiving intravitreal ranibizumab were divided into first eye (Group A, n=35) and second eye (Group B, n=40) cohorts.
- Visual acuity and contrast sensitivity were measured before treatment and 3 months after the third injection.
- Outcomes were compared between groups using 95% confidence intervals.
Main Results:
- Pretreatment visual acuity was better in Group B (0.66 logMar) than Group A (0.86 logMar).
- Posttreatment, both groups showed significant visual acuity improvement (Group A: 0.63 logMar, Group B: 0.44 logMar).
- Mean letter gain was similar (11.1 in Group A, 10.6 in Group B), with 50% of patients gaining >=15 letters. Contrast sensitivity improved in both groups.
Conclusions:
- Second eye patients typically present with better visual acuity and have a higher potential for better posttreatment outcomes.
- Despite baseline differences, both first and second eye patients have an equal likelihood of achieving significant visual improvement with ranibizumab treatment.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...